A Biomarker-Based Proof-of-Mechanism Study of NPT520-34 in Patients with Neurodegenerative Disorders
Latest Information Update: 15 Jan 2020
At a glance
- Drugs NPT520 34 (Primary)
- Indications Neurodegenerative disorders
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Sponsors Neuropore Therapies
Most Recent Events
- 13 Jan 2020 According to a Neuropore Therapies media release, the company is evaluating the optimal study design and patient population for the study.
- 15 May 2019 New trial record
- 08 May 2019 According to a Neuropore Therapies media release, this study is scheduled to start in 2020.